# Maneesh Jain

> Maneesh Jain is the CEO and Co-founder of Mirvie, a South San Francisco-based biotech company pioneering RNA-based blood tests to predict pregnancy complications like preeclampsia and preterm birth months before symptoms occur. A serial entrepreneur with 20+ years in life sciences and more than $1.5B in combined exits across five prior startups - including Ion Torrent (acquired by Life Technologies) and Cirina (acquired by GRAIL) - Jain trained at the Stanford Genome Technology Center and holds a BS from Caltech and a Master's in Applied Physics from Stanford. Mirvie has raised over $90 million from investors including Khosla Ventures, GV, General Catalyst, and the Gates Foundation, and received FDA Breakthrough Device Designation for its preeclampsia risk test in 2022.

- **Role:** CEO & Co-founder at Mirvie
- **Organizations:** Mirvie, Ion Torrent, Butterfly Network, Cirina, ParAllele BioScience, Auriphex Bioscience
- **Nationality:** American
- **Education:** BS, California Institute of Technology (Caltech), Master's in Applied Physics, Stanford University, Research Training, Stanford Genome Technology Center
- **Known for:** Five successful biotech startups with combined exits exceeding $1.5B in value, Founded Ion Torrent (2007) - pioneered ion semiconductor DNA sequencing, acquired by Life Technologies, Co-founded Cirina with Dennis Lo - liquid biopsy company acquired by GRAIL

## Career timeline

- **1990** — Graduated from Caltech with a BS degree
- **Early 1990s** — Completed Master's in Applied Physics at Stanford; trained at Stanford Genome Technology Center
- **~2000** — Co-founded ParAllele BioScience, an early-stage genomics company
- **~2003** — Co-founded Auriphex Bioscience; company acquired by Affymetrix
- **2007** — Founded Ion Torrent, pioneering ion semiconductor DNA sequencing technology
- **2010** — Ion Torrent acquired by Life Technologies (later part of Thermo Fisher Scientific)
- **~2012** — Joined Butterfly Network as President and COO; helped raise $100M+ and achieve FDA clearance for handheld ultrasound
- **2014** — Co-founded Cirina with Dennis Lo to develop blood-plasma tests for early disease detection
- **~2017** — Cirina acquired by GRAIL, advancing the liquid biopsy field
- **2018** — Co-founded Mirvie with Stephen Quake to build RNA-based diagnostics for pregnancy health
- **2022** — Mirvie published landmark RNA study in Nature covering 2,539 blood samples; raised $60M Series B; received FDA Breakthrough Device Designation for preeclampsia test
- **2023** — Mirvie achieved CLIA certification, first RNA-based pregnancy health company to do so
- **2025** — Mirvie's Encompass test recognized as one of TIME's Best Inventions of 2025; Jain speaks at SXSW; company raises additional venture funding

## Achievements

- Five successful biotech startups with combined exits exceeding $1.5B in value
- Founded Ion Torrent (2007) - pioneered ion semiconductor DNA sequencing, acquired by Life Technologies
- Co-founded Cirina with Dennis Lo - liquid biopsy company acquired by GRAIL
- Led Mirvie to FDA Breakthrough Device Designation for first preeclampsia prediction blood test (2022)
- Mirvie's RNA platform showed 75% detection rate for preeclampsia and 76% for early preterm birth in clinical studies
- Published landmark RNA pregnancy health study in Nature (January 2022)
- Secured CLIA certification for Mirvie - first RNA-based pregnancy health company to achieve this
- Raised $90M+ for Mirvie with investors including Khosla Ventures, GV, General Catalyst, BlackRock, Foresite Capital, and Gates Foundation
- Attracted Olympic gold medalist Allyson Felix as a Mirvie investor
- Mirvie's Encompass test named one of TIME's Best Inventions of 2025
- Speaker at SXSW 2025

## Latest updates

- **2025-09** — Mirvie raises additional venture funding (most recent round as of late 2025)
- **2025-05** — Mirvie's Encompass test named one of TIME's Best Inventions of 2025
- **2025-03** — Maneesh Jain speaks at SXSW 2025
- **2023-09** — Mirvie achieves CLIA certification for high-complexity clinical testing - first RNA-based pregnancy health company to do so
- **2022-05** — Mirvie raises $60M Series B; receives FDA Breakthrough Device Designation for preeclampsia prediction test
- **2022-01** — Landmark RNA pregnancy health study published in Nature covering 2,539 blood samples from 1,840 women

## Links

- Website: https://mirvie.com
- LinkedIn: http://www.linkedin.com/in/maneesh-jain-2509388
- Twitter/X: https://twitter.com/jainmaneeshjain
- Facebook: https://www.facebook.com/MirvieDx/

---

Profile page: https://yespress.io/maneesh-jain
Published by YesPress — https://yespress.io
Last updated: 2026-05-13